Zhang Shuzhong, Yang Xinning, Coburn Robert A, Morris Marilyn E
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, 517 Hochstetter Hall, University at Buffalo, State University of New York, Amherst, NY 14260-1200, USA.
Biochem Pharmacol. 2005 Aug 15;70(4):627-39. doi: 10.1016/j.bcp.2005.05.017.
Breast cancer resistance protein (BCRP) is a newly identified ABC transporter, which plays an important role in drug disposition and represents an additional mechanism for the development of MDR. Flavonoids, a major class of natural compounds widely present in foods and herbal products, have been shown to be BCRP inhibitors. The objective of the present study was to elucidate the SAR and derive a QSAR model for flavonoid-BCRP interaction. The EC(50) values for increasing mitoxantrone accumulation in MCF-7 MX100 cells for 25 flavonoids, from five flavonoid subclasses, were determined in this study or obtained from our previous publication [Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263-73], and ranged from 0.07+/-0.02 microM to 183+/-21.7 microM. We found that the presence of a 2,3-double bond in ring C, ring B attached at position 2, hydroxylation at position 5, lack of hydroxylation at position 3 and hydrophobic substitution at positions 6, 7, 8 or 4', are important structural properties important for potent flavonoid-BCRP interaction. These structural requirements are similar but not identical to those for potent flavonoid-NBD2 (P-glycoprotein) interaction, indicating that inhibition of BCRP by flavonoids may involve, in part, the binding of flavonoids with the NBD of BCRP. In addition, a QSAR model consisting three structural descriptors was constructed, and both internally and externally validated, suggesting the model could be used to quantitatively predict BCRP inhibition activity of flavonoids. These findings should be useful for predicting BCRP inhibition activity of other untested flavonoids and for guiding the synthesis of potent BCRP inhibitors for potential clinical application.
乳腺癌耐药蛋白(BCRP)是一种新发现的ABC转运蛋白,在药物处置中起重要作用,是多药耐药(MDR)产生的另一种机制。黄酮类化合物是广泛存在于食品和草药产品中的一大类天然化合物,已被证明是BCRP抑制剂。本研究的目的是阐明黄酮类化合物与BCRP相互作用的构效关系(SAR)并推导定量构效关系(QSAR)模型。本研究测定了或从我们之前的出版物[Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263 - 73]中获得了来自五个黄酮子类别的25种黄酮类化合物在MCF - 7 MX100细胞中增加米托蒽醌蓄积的半数有效浓度(EC50)值,范围为0.07±0.02μM至183±21.7μM。我们发现,C环中存在2,3 - 双键、B环连接在2位、5位羟基化、3位无羟基化以及6、7、8或4'位的疏水取代是黄酮类化合物与BCRP有效相互作用的重要结构特性。这些结构要求与黄酮类化合物与NBD2(P - 糖蛋白)有效相互作用的要求相似但不完全相同,表明黄酮类化合物对BCRP的抑制作用可能部分涉及黄酮类化合物与BCRP的NBD结合。此外,构建了一个由三个结构描述符组成的QSAR模型,并进行了内部和外部验证,表明该模型可用于定量预测黄酮类化合物的BCRP抑制活性。这些发现对于预测其他未测试黄酮类化合物的BCRP抑制活性以及指导合成用于潜在临床应用的有效BCRP抑制剂应是有用的。